New York hospitals will trial using antibodies to treat coronavirus cases

Back in our exhaustive review of potential treatments for SARS-CoV-2 infections, we mentioned one option that was relatively quick, easy, and required no further approval for use: transfer of blood plasma from those who had previously had an infection. The reasoning being that this plasma will contain antibodies that could neutralize coronaviruses in the blood stream, severely limiting the progression of an active infection. Now, trials of this method are starting in New York City, the hardest hit location in the US.

There have been some anecdotal reports of the approach being used by countries like China, which were hit hard early in the pandemic; one published today indicated that plasma treatment improved the condition of five critically ill patients. But no detailed studies of its effectiveness have been reported so far (at least to our ability to determine). That may now be about to change, according to the New York Times.

Several New York City hospitals are planning a joint test of plasma transfusions as a therapy, relying on the large and growing population of formerly infected people in the area. Initially, it will be tested in those who are suffering COVID-19 symptoms who require hospitalization but who have not progressed to severe breathing impairment. The Food and Drug Administration approved the research on Tuesday.